STAAR Surgical Announces Q4 and FY 2025 Earnings Release Date
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy STAA?
Source: Yahoo Finance
- Earnings Release Schedule: STAAR Surgical will release its fourth quarter and fiscal year 2025 financial results on March 3, 2026, after market close, providing crucial operational and financial data to help investors assess the company's performance.
- Conference Call Details: The company will host a conference call at 5:30 PM ET on the same day to discuss financial results and business progress, covering topics such as fiscal year 2025 operations review, inventory normalization, and cost discipline, aimed at boosting investor confidence.
- Manufacturing Expansion Update: During the call, STAAR will provide updates on its manufacturing expansion in Switzerland, indicating strategic positioning in response to global market demand recovery, which may enhance production capacity and market responsiveness.
- Innovation Pipeline Progress: The company will also share the latest developments in its innovation pipeline, showcasing ongoing R&D investments in the vision correction field, further solidifying its leadership position in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STAA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STAA
Wall Street analysts forecast STAA stock price to rise
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 19.900
Low
30.75
Averages
30.75
High
30.75
Current: 19.900
Low
30.75
Averages
30.75
High
30.75
About STAA
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
STAAR Surgical to Announce Q4 Earnings on March 3
- Earnings Announcement: STAAR Surgical is set to release its Q4 earnings on March 3 after market close, with a consensus EPS estimate of $0.17, reflecting a significant year-over-year increase of 124.6%, which could boost investor confidence.
- Revenue Expectations: The company anticipates Q4 revenue of $75.05 million, representing a 53.3% year-over-year growth, indicating strong market competitiveness and rising product demand.
- Performance Forecast Revisions: Over the past year, STAAR Surgical has beaten EPS estimates 50% of the time, while only achieving a 25% beat rate on revenue estimates, highlighting volatility in its profitability.
- Shareholder Activity: Yunqi Capital recently purchased 750,000 shares of STAAR Surgical at $21.53 per share, indicating institutional investor confidence in the company's future performance, which may positively impact the stock price.
See More
STAAR Surgical to Release Q4 and FY 2025 Financial Results
- Earnings Release Schedule: STAAR Surgical will release its fourth quarter and fiscal year 2025 financial results on March 3, 2026, after market close, demonstrating the company's commitment to financial transparency.
- Conference Call Details: The company will host a conference call at 5:30 PM ET on the same day to discuss fiscal year 2025 operations and financial results, expected to cover critical topics such as recovery in China and operational improvements, reflecting STAAR's keen awareness of market dynamics.
- Innovation and Expansion: The call will provide updates on manufacturing expansion in Switzerland and the innovation pipeline, indicating STAAR's ongoing investment in technology and market expansion aimed at enhancing its competitiveness in the global vision correction market.
- Long-Term Vision: Since 1982, STAAR Surgical has focused on ophthalmic surgery, selling over 3.5 million implantable lenses in 75 countries, showcasing its leadership position in the industry and confidence in future growth.
See More
STAAR Surgical Announces Q4 and FY 2025 Earnings Release Date
- Earnings Release Schedule: STAAR Surgical will release its fourth quarter and fiscal year 2025 financial results on March 3, 2026, after market close, providing crucial operational and financial data to help investors assess the company's performance.
- Conference Call Details: The company will host a conference call at 5:30 PM ET on the same day to discuss financial results and business progress, covering topics such as fiscal year 2025 operations review, inventory normalization, and cost discipline, aimed at boosting investor confidence.
- Manufacturing Expansion Update: During the call, STAAR will provide updates on its manufacturing expansion in Switzerland, indicating strategic positioning in response to global market demand recovery, which may enhance production capacity and market responsiveness.
- Innovation Pipeline Progress: The company will also share the latest developments in its innovation pipeline, showcasing ongoing R&D investments in the vision correction field, further solidifying its leadership position in the global market.
See More
FDA Approves Expanded Age Indication for Staar Surgical's EVO ICL
- Expanded Age Indication: The FDA has approved Staar Surgical's EVO ICL for patients aged 21 to 60, expanding the potential market by nearly 8 million refractive patients, significantly enhancing growth opportunities.
- Clinical Trial Safety: The three-year follow-up of 629 eyes in the FDA clinical trial demonstrated a strong safety profile with a safety index of 1.25, no reported cases of pupillary block or pigment dispersion, and a low anterior subcapsular cataract incidence of 0.16%.
- Shifting Market Trends: The EVO ICL has become the leading procedure for patients with -8.0 diopters and above, with over half of U.S. vision correction consumers now interested in alternatives to LASIK, indicating a shift towards lens-based solutions.
- Stock Performance Analysis: Despite a 2.28% premarket increase to $16.57 following the FDA approval, the stock remains below its 20-day and 100-day simple moving averages, indicating a bearish trend, with key support at $14.50 to monitor closely.
See More
FDA Expands EVO ICL Age Indication to 60 Years
- Market Expansion: The FDA's approval to extend the age range for EVO ICL to 21-60 years opens access to nearly 8 million additional refractive patients, significantly enlarging STAAR Surgical's potential customer base in the U.S. market.
- Shift in Surgical Preference: As demand for laser refractive surgeries declines by nearly 40%, EVO ICL implantations continue to grow, with over 53% of patients expressing interest in alternatives to LASIK, indicating a meaningful shift in patient preferences for vision correction methods.
- Leading Treatment for High Myopia: EVO ICL has become the most performed refractive procedure for patients with -8.0 diopters and above, capturing 72% of the market share, demonstrating that this technology is reshaping the treatment paradigm for high myopia to meet increasing demand.
- Long-Term Safety Validation: FDA clinical trials indicate a safety index of 1.25 over three years for 629 eyes, with no reported cases of pupillary block or pigment dispersion and a low incidence of anterior subcapsular cataract at 0.16%, further reinforcing the safety and efficacy of EVO ICL.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific stock names are not mentioned, such rating changes typically lead to price fluctuations in the affected stocks, prompting investors to closely monitor these adjustments for portfolio optimization.
- Market Reaction Expectations: Analyst rating adjustments may trigger short-term market reactions, especially when investor sentiment is sensitive towards certain stocks, thereby impacting overall market sentiment.
- Information Access Channels: Investors can access a comprehensive view of rating changes through Benzinga's analyst ratings page, enabling them to make more informed investment decisions.
See More
STAAR Surgical to Announce Q4 Earnings on March 3
- Earnings Announcement: STAAR Surgical is set to release its Q4 earnings on March 3 after market close, with a consensus EPS estimate of $0.17, reflecting a significant year-over-year increase of 124.6%, which could boost investor confidence.
- Revenue Expectations: The company anticipates Q4 revenue of $75.05 million, representing a 53.3% year-over-year growth, indicating strong market competitiveness and rising product demand.
- Performance Forecast Revisions: Over the past year, STAAR Surgical has beaten EPS estimates 50% of the time, while only achieving a 25% beat rate on revenue estimates, highlighting volatility in its profitability.
- Shareholder Activity: Yunqi Capital recently purchased 750,000 shares of STAAR Surgical at $21.53 per share, indicating institutional investor confidence in the company's future performance, which may positively impact the stock price.
See More
STAAR Surgical to Release Q4 and FY 2025 Financial Results
- Earnings Release Schedule: STAAR Surgical will release its fourth quarter and fiscal year 2025 financial results on March 3, 2026, after market close, demonstrating the company's commitment to financial transparency.
- Conference Call Details: The company will host a conference call at 5:30 PM ET on the same day to discuss fiscal year 2025 operations and financial results, expected to cover critical topics such as recovery in China and operational improvements, reflecting STAAR's keen awareness of market dynamics.
- Innovation and Expansion: The call will provide updates on manufacturing expansion in Switzerland and the innovation pipeline, indicating STAAR's ongoing investment in technology and market expansion aimed at enhancing its competitiveness in the global vision correction market.
- Long-Term Vision: Since 1982, STAAR Surgical has focused on ophthalmic surgery, selling over 3.5 million implantable lenses in 75 countries, showcasing its leadership position in the industry and confidence in future growth.
See More
STAAR Surgical Announces Q4 and FY 2025 Earnings Release Date
- Earnings Release Schedule: STAAR Surgical will release its fourth quarter and fiscal year 2025 financial results on March 3, 2026, after market close, providing crucial operational and financial data to help investors assess the company's performance.
- Conference Call Details: The company will host a conference call at 5:30 PM ET on the same day to discuss financial results and business progress, covering topics such as fiscal year 2025 operations review, inventory normalization, and cost discipline, aimed at boosting investor confidence.
- Manufacturing Expansion Update: During the call, STAAR will provide updates on its manufacturing expansion in Switzerland, indicating strategic positioning in response to global market demand recovery, which may enhance production capacity and market responsiveness.
- Innovation Pipeline Progress: The company will also share the latest developments in its innovation pipeline, showcasing ongoing R&D investments in the vision correction field, further solidifying its leadership position in the global market.
See More
FDA Approves Expanded Age Indication for Staar Surgical's EVO ICL
- Expanded Age Indication: The FDA has approved Staar Surgical's EVO ICL for patients aged 21 to 60, expanding the potential market by nearly 8 million refractive patients, significantly enhancing growth opportunities.
- Clinical Trial Safety: The three-year follow-up of 629 eyes in the FDA clinical trial demonstrated a strong safety profile with a safety index of 1.25, no reported cases of pupillary block or pigment dispersion, and a low anterior subcapsular cataract incidence of 0.16%.
- Shifting Market Trends: The EVO ICL has become the leading procedure for patients with -8.0 diopters and above, with over half of U.S. vision correction consumers now interested in alternatives to LASIK, indicating a shift towards lens-based solutions.
- Stock Performance Analysis: Despite a 2.28% premarket increase to $16.57 following the FDA approval, the stock remains below its 20-day and 100-day simple moving averages, indicating a bearish trend, with key support at $14.50 to monitor closely.
See More
FDA Expands EVO ICL Age Indication to 60 Years
- Market Expansion: The FDA's approval to extend the age range for EVO ICL to 21-60 years opens access to nearly 8 million additional refractive patients, significantly enlarging STAAR Surgical's potential customer base in the U.S. market.
- Shift in Surgical Preference: As demand for laser refractive surgeries declines by nearly 40%, EVO ICL implantations continue to grow, with over 53% of patients expressing interest in alternatives to LASIK, indicating a meaningful shift in patient preferences for vision correction methods.
- Leading Treatment for High Myopia: EVO ICL has become the most performed refractive procedure for patients with -8.0 diopters and above, capturing 72% of the market share, demonstrating that this technology is reshaping the treatment paradigm for high myopia to meet increasing demand.
- Long-Term Safety Validation: FDA clinical trials indicate a safety index of 1.25 over three years for 629 eyes, with no reported cases of pupillary block or pigment dispersion and a low incidence of anterior subcapsular cataract at 0.16%, further reinforcing the safety and efficacy of EVO ICL.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific stock names are not mentioned, such rating changes typically lead to price fluctuations in the affected stocks, prompting investors to closely monitor these adjustments for portfolio optimization.
- Market Reaction Expectations: Analyst rating adjustments may trigger short-term market reactions, especially when investor sentiment is sensitive towards certain stocks, thereby impacting overall market sentiment.
- Information Access Channels: Investors can access a comprehensive view of rating changes through Benzinga's analyst ratings page, enabling them to make more informed investment decisions.
See More
